Document is current
Any future updates will be listed below
-
Authors
Wessendorf, Joel https://orcid.org/0009-0007-0273-2183
Spektor, Anna-Maria
Aboulmaouahib, Brahim
Daum, Johanna
Glatting, Frederik M.
Schlamp, Kai
Grott, Matthias
Eichhorn, Florian
Heußel, Claus Peter
Kauczor, Hans Ulrich
Kreuter, Michael
Schreckenberger, Mathias
Winter, Hauke
Haberkorn, Uwe
Röhrich, Manuel
-
Funding
Funding for this research was provided by:
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
- License Information
-
More Information
Article History
Received: 11 December 2024
Accepted: 25 May 2025
First Online: 12 June 2025
Declarations
:
: All procedures performed in studies involving human participants confirmed to the ethical standards of the institutional and/or national research committee and to the Helsinki declaration (1964) and its later amendments or comparable ethical standards. This retrospective study was approved by the local advisory ethic committee (study number S-115/2020).
: All patients have given written consent to publication.
: U.H. has filed a patent application for quinoline-based FAP-targeting agents for imaging and therapy in nuclear medicine. U.H. also has shares of a consultancy group for iTheranostics.
